Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Haase

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Obesity Science & Practice|September 3, 2020
Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support programSean Wharton, Christiane L Haase, Elham Kamran, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|June 10, 2016
Effectiveness of intensification therapies in Danes with Type 2 diabetes who use basal insulin: a population-based studyR W Thomsen, L M Baggesen, M Søgaard, et al.
Diabetes Care|April 14, 2017
Early Glycemic Control and Magnitude of HbA<sub>1c</sub> Reduction Predict Cardiovascular Events and Mortality: Population-Based Cohort Study of 24,752 Metformin InitiatorsElisabeth Svensson, Lisbeth M Baggesen, Søren P Johnsen, et al.
Diabetes, Obesity & Metabolism|May 2, 2015
Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort studyR W Thomsen, L M Baggesen, E Svensson, et al.
Diabetologia|August 17, 2015
Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetesReimar W Thomsen, Lisbeth M Baggesen, Mette Søgaard, et al.
Urology|February 25, 2003
Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cellsG Fechner, F G E Perabo, D H Schmidt, et al.
Obesity Science & Practice|September 3, 2020
Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in CanadaSean Wharton, Christiane L Haase, Elham Kamran, et al.
Obesity (Silver Spring, Md.)|September 24, 2019
Response to "Liraglutide Effectiveness: Is There a Real-World Clinical Benefit?"Sean Wharton, Aiden Liu, Arash Pakseresht, et al.
Obesity (Silver Spring, Md.)|May 8, 2019
Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in CanadaSean Wharton, Aiden Liu, Arash Pakseresht, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 15, 2016
Patient-level predictors of achieving early glycaemic control in Type 2 diabetes mellitus: a population-based studyE Svensson, L M Baggesen, R W Thomsen, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Obesity Science & Practice|September 3, 2020
Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support programSean Wharton, Christiane L Haase, Elham Kamran, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|June 10, 2016
Effectiveness of intensification therapies in Danes with Type 2 diabetes who use basal insulin: a population-based studyR W Thomsen, L M Baggesen, M Søgaard, et al.
Diabetes Care|April 14, 2017
Early Glycemic Control and Magnitude of HbA<sub>1c</sub> Reduction Predict Cardiovascular Events and Mortality: Population-Based Cohort Study of 24,752 Metformin InitiatorsElisabeth Svensson, Lisbeth M Baggesen, Søren P Johnsen, et al.
Diabetes, Obesity & Metabolism|May 2, 2015
Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort studyR W Thomsen, L M Baggesen, E Svensson, et al.
Diabetologia|August 17, 2015
Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetesReimar W Thomsen, Lisbeth M Baggesen, Mette Søgaard, et al.
Urology|February 25, 2003
Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cellsG Fechner, F G E Perabo, D H Schmidt, et al.
Obesity Science & Practice|September 3, 2020
Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in CanadaSean Wharton, Christiane L Haase, Elham Kamran, et al.
Obesity (Silver Spring, Md.)|September 24, 2019
Response to "Liraglutide Effectiveness: Is There a Real-World Clinical Benefit?"Sean Wharton, Aiden Liu, Arash Pakseresht, et al.
Obesity (Silver Spring, Md.)|May 8, 2019
Real-World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in CanadaSean Wharton, Aiden Liu, Arash Pakseresht, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 15, 2016
Patient-level predictors of achieving early glycaemic control in Type 2 diabetes mellitus: a population-based studyE Svensson, L M Baggesen, R W Thomsen, et al.
Pageof 4